Sanofi (EURONEXT: SAN and NYSE: SNY) and Pluromed Inc. have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts. The acquisition is subject to customary closing conditions.

In February 2011, GSK announced its intention to divest non-core Consumer Healthcare over-the-counter (OTC) products predominantly in the United States and Europe with aggregate sales of approximately £500 million.

Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a request for additional information, often referred to as a "second request," from the Federal Trade Commission ("FTC") in connection with Roche's proposed acquisition of Illumina, Inc. (NASDAQ: ILMN)

AstraZeneca filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA's denial on 7 March 2012 of Citizen Petitions filed by AstraZeneca with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.

Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation.

Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 shareholders in attendance, representing 87.4% of a total of 160,000,000 bearer shares, approved Roche's 2011 Annual Report and Financial Statements.